Howard Marks
Oaktree Capital Management
Howard Marks Arbor Rapha Capital Bioholdings Corp I stake
total: 853
Oaktree Capital Management ARCK trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2021 Q4
- Held for:
- 4 quarters
- Latest activity:
- 2022 Q4
According to 2026 Q2 report, Howard Marks doesn't hold any Arbor Rapha Capital Bioholdings Corp I (ARCK) shares. To date, the estimated cost basis is nearly $9.95 for "buy" trades and estimated average "sell" price is $10.12. Oaktree Capital Management first purchased ARCK in 2021 Q4, initially acquiring 100,000 shares. Since the initial investment in Arbor Rapha Capital Bioholdings Corp I (ARCK), Oaktree Capital Management has made 1 more transaction.
When did Howard Marks sell Arbor Rapha Capital Bioholdings Corp I (ARCK)?
Howard Marks sold off the entire Arbor Rapha Capital Bioholdings Corp I (ARCK) position in 2022 Q4.
When did Howard Marks buy Arbor Rapha Capital Bioholdings Corp I (ARCK)?
Howard Marks first invested in Arbor Rapha Capital Bioholdings Corp I (ARCK) in 2021 Q4 at the reported quarter-end price of $9.95 per share.
What's the cost basis of Oaktree Capital Management's ARCK stake?
The estimated cost basis for Arbor Rapha Capital Bioholdings Corp I (ARCK) stake is around $9.95 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $9.95
- Weighted AVG sell price:
- $10.12
Howard Marks's historical trades in Arbor Rapha Capital Bioholdings Corp I
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q4
|
0.00%
|
0
|
$10.12
|
|
-100% (-100,000)
|
-0.01%
|
|
2021 Q4
|
0.01%
|
100,000
|
$9.95
|
$995,000
|
new
|
+0.01%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.